BR112015007731A2 - pde9i com cadeia principal de imidazo pirazinona - Google Patents

pde9i com cadeia principal de imidazo pirazinona

Info

Publication number
BR112015007731A2
BR112015007731A2 BR112015007731A BR112015007731A BR112015007731A2 BR 112015007731 A2 BR112015007731 A2 BR 112015007731A2 BR 112015007731 A BR112015007731 A BR 112015007731A BR 112015007731 A BR112015007731 A BR 112015007731A BR 112015007731 A2 BR112015007731 A2 BR 112015007731A2
Authority
BR
Brazil
Prior art keywords
pde9i
compound
formula
effective amount
therapeutically effective
Prior art date
Application number
BR112015007731A
Other languages
English (en)
Other versions
BR112015007731B1 (pt
Inventor
Juhl Karsten
Wen Kate
Baek Simonsen Klaus
Kyhn Rasmussen Lars
Langgård Morten
Svenstrup Niels
Wang Yazhou
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112015007731A2 publication Critical patent/BR112015007731A2/pt
Publication of BR112015007731B1 publication Critical patent/BR112015007731B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo “pde9i com cadeia principal de imidazo pirazinona” esta invenção é dirigida a compostos, que são inibidores da enzima pde9. a invenção proporciona uma composição farmacêutica compreendendo uma quantidade terapeuticamente eficaz de um composto da invenção e um veículo farmaceuticamente aceitável. a presente invenção também proporciona processos para a preparação dos compostos de fórmula (i). a presente invenção proporciona ainda um método de tratamento de um sujeito que sofre de um distúrbio neurodegenerativo que compreende a administração ao sujeito de uma quantidade terapeuticamente eficaz de um composto de fórmula (i). a presente invenção proporciona ainda um método de tratamento de um sujeito sofrendo de um distúrbio psiquiátrico, compreendendo a administração ao sujeito de uma quantidade terapeuticamente eficaz de um composto de fórmula (i) 1/1
BR112015007731-5A 2011-10-10 2012-10-09 Composto, composição farmacêutica que o compreende e uso do mesmo BR112015007731B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011001692 2011-10-10
PCT/EP2012/069936 WO2013053690A1 (en) 2011-10-10 2012-10-09 Pde9i with imidazo pyrazinone backbone

Publications (2)

Publication Number Publication Date
BR112015007731A2 true BR112015007731A2 (pt) 2017-07-04
BR112015007731B1 BR112015007731B1 (pt) 2022-05-31

Family

ID=47019007

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015007731-5A BR112015007731B1 (pt) 2011-10-10 2012-10-09 Composto, composição farmacêutica que o compreende e uso do mesmo

Country Status (15)

Country Link
US (2) US9643970B2 (pt)
EP (2) EP3121178B1 (pt)
JP (1) JP2015531401A (pt)
CN (2) CN104703987B (pt)
AU (2) AU2012323085B2 (pt)
BR (1) BR112015007731B1 (pt)
CA (1) CA2886885C (pt)
HK (1) HK1211023A1 (pt)
IL (2) IL237836A (pt)
IN (1) IN2015DN02829A (pt)
MA (1) MA37958B1 (pt)
MX (1) MX370433B (pt)
SG (1) SG11201502728WA (pt)
TN (1) TN2015000100A1 (pt)
WO (1) WO2013053690A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3121178B1 (en) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
JO3627B1 (ar) * 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
ES2971969T3 (es) 2015-07-07 2024-06-10 H Lundbeck As Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas
TW201717948A (zh) * 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
TN2018000119A1 (en) * 2015-11-09 2019-10-04 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
KR102664509B1 (ko) 2016-04-22 2024-05-10 인사이트 코포레이션 Lsd1 억제제의 제제
CN109475556A (zh) 2016-07-06 2019-03-15 伊马拉公司 用于治疗外周疾病的pde9抑制剂
JP7112413B2 (ja) * 2016-10-18 2022-08-03 ハー・ルンドベック・アクチエゼルスカベット Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン
AU2017350477A1 (en) * 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
PL3532064T3 (pl) 2016-10-28 2020-11-16 H. Lundbeck A/S Terapie skojarzone obejmujące imidazopirazynony do leczenia zaburzeń psychiatrycznych i/lub poznawczych
EP3585790A1 (en) * 2017-02-27 2020-01-01 Janssen Pharmaceutica NV [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors
US11370795B2 (en) * 2017-05-26 2022-06-28 Imara Inc. Process for the synthesis of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
CN111051308A (zh) 2017-06-08 2020-04-21 默沙东公司 吡唑并嘧啶pde9抑制剂
EP3713936B1 (en) 2017-11-23 2021-10-20 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
HRP20240363T1 (hr) * 2018-05-25 2024-06-07 Cardurion Pharmaceuticals, Inc. Monohidratni i kristalni oblici 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a] pirazin-8-ona
US20210115040A1 (en) * 2018-06-20 2021-04-22 Janssen Pharmaceutica Nv Oga inhibitor compounds
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020206336A1 (en) * 2019-04-05 2020-10-08 Imara Inc. Pde9 inhibitors for treating sickle cell disease
WO2020227399A1 (en) * 2019-05-07 2020-11-12 Imara Inc. Pde9 inhibitors for treating thalassemia
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295436A1 (de) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase V Inhibitoren
HUP0105132A3 (en) 1999-01-20 2002-12-28 Dresden Arzneimittel Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CN1575191A (zh) 2001-11-02 2005-02-02 辉瑞产品公司 用pde9抑制剂治疗胰岛素耐受性综合征和ⅱ型糖尿病
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0416118A (pt) 2003-10-31 2007-01-02 Pfizer Prod Inc inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
EP2123801A4 (en) 2006-09-08 2011-01-19 Tokuyama Corp METHOD AND DEVICE FOR PREPARING GROUP III NITRIDE
CN101557826A (zh) 2006-12-13 2009-10-14 Aska制药株式会社 泌尿系统疾病的治疗药
KR101563103B1 (ko) 2006-12-13 2015-10-23 아스카 세이야쿠 가부시키가이샤 퀴녹살린 유도체
PL2152712T3 (pl) * 2007-05-11 2012-05-31 Pfizer Związki aminoheterocykliczne
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
PL2619208T3 (pl) * 2010-09-20 2017-03-31 Ironwood Pharmaceuticals, Inc. Związki imidazotriazynonu
BR112014007912B1 (pt) 2011-10-07 2022-06-07 Eisai R&D Management Co., Ltd Derivados de pirazoloquinolina
EP3121178B1 (en) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds

Also Published As

Publication number Publication date
US20150274736A1 (en) 2015-10-01
BR112015007731B1 (pt) 2022-05-31
MX370433B (es) 2019-12-13
US9643970B2 (en) 2017-05-09
EP2906562B1 (en) 2016-10-05
CN106905324A (zh) 2017-06-30
MA37958B1 (fr) 2018-10-31
SG11201502728WA (en) 2015-05-28
AU2012323085A1 (en) 2015-04-02
EP2906562A1 (en) 2015-08-19
AU2017201873A1 (en) 2017-04-06
IN2015DN02829A (pt) 2015-09-11
AU2012323085B2 (en) 2017-03-09
JP2015531401A (ja) 2015-11-02
US9993477B2 (en) 2018-06-12
EP3121178A1 (en) 2017-01-25
CN104703987B (zh) 2017-05-03
CA2886885C (en) 2019-07-16
IL237836A (en) 2017-07-31
AU2017201873B2 (en) 2018-03-29
CN106905324B (zh) 2018-09-25
AU2017201873C1 (en) 2018-08-02
MX2015004422A (es) 2015-10-15
CA2886885A1 (en) 2013-04-18
WO2013053690A1 (en) 2013-04-18
CN104703987A (zh) 2015-06-10
US20170173018A1 (en) 2017-06-22
IL253448A0 (en) 2017-09-28
EP3121178B1 (en) 2018-09-19
TN2015000100A1 (en) 2016-06-29
MA37958A1 (fr) 2017-11-30
HK1211023A1 (en) 2016-05-13

Similar Documents

Publication Publication Date Title
BR112015007731A2 (pt) pde9i com cadeia principal de imidazo pirazinona
BR112014018199A8 (pt) inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
CO6321263A2 (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BR112012014486A2 (pt) derivados de aril triazol heteroaromático como inibidaores de enzima pde10a
CO6612246A2 (es) Derivados de 2-arilimidazol como inhibidores de enzima pde10a
CR20120319A (es) Derivados de fenilimidazol heteroaromáticos como inhibidores de enzima pde10a
UA102693C2 (ru) Производные фенилимидазола как ингибиторы фермента pde10a
UA112065C2 (uk) Похідні імідазолу як інгібітори ферменту pde10a
TN2014000288A1 (en) Pde9 inhibitors with imidazo triazinone backbone
CY1116689T1 (el) Παραγωγα ιμιδαζολης ως αναστολεις του ενζυμου pde10a
DOP2013000108A (es) Derivados de imidazol como inhibidores de la enzima pde10a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2012, OBSERVADAS AS CONDICOES LEGAIS